Abstract:1065 Background: Triple-negative breast cancer (TNBC) has been shown to display cyclin-dependent kinase 7 (CDK7)-dependent transcriptional addition and is sensitive to a CDK7 inhibitor THZ1. As tumor heterogeneity is well known, we sought to identify predictive markers of sensitivity to CDK7 inhibition in TNBC. Methods: Published mRNA microarray data was analyzed to identify genes associated with sensitivity of TNBC cells to the CDK7 inhibitor THZ1. Cell survival assay after THZ1 treatment was performed using Cell Counting Kit-8. Expression of SOX9 was examined by Western blot in cell lines and IHC in breast cancer tissue microarray. Patient survival analysis was done using the Kaplan-Meier method. Results: Analysis of published mRNA microarray data showed that SOX9 was overexpressed in the MDA-468 and BT-549 TNBC cell lines, which were sensitive to the CDK7 inhibitor THZ1 and showed decreased SOX9 expression with THZ1 treatment. We treated 10 TNBC cell lines with various concentrations of THZ1 and found that these cell lines displayed a wide spectrum of sensitivity to THZ1, with an IC50 ranging from 20-30 nM in sensitive lines (MDA-468 and MDA-231) to ~300 nM in insensitive lines (BT-20 and MDA-157). There was a strong correlation of SOX9 expression by Western blot and sensitivity to THZ1 in these cell lines (Pearson correlation, r = 0.82, P= 0.01). IHC of two tissue microarrays containing 278 breast cancer samples showed that SOX9 expression was significantly higher in TNBC (n = 59) compared to hormone positive breast cancer (n = 173; P< 0.01). Among the 59 TNBC cases, 43 had high SOX9 expression and 16 had low SOX9 expression. Patients with high or low SOX expression had similar grade, T stage and nodal involvement (All P> 0.20). Finally, with standard of care treatment, TNBC patients with high SOX9 expression had a significantly worse overall survival (OS) compared to patients with low SOX9 expression (2 year OS rate 100% vs 92.9%, 5 year OS rate 93.8% vs 83.3%, log rank P= 0.03). Conclusions: SOX9 expression level in TNBC cell lines was associated with sensitivity to the CDK7 inhibitor THZ1. TNBC patients with high expression of SOX9 had worse OS, and may benefit from CDK7 inhibition as a novel therapy.

SOX9 promotes stemness in the CAL27 cell line of tongue squamous cell carcinoma

Upregulation of sex-determining region Y-box 9 (SOX9) promotes cell proliferation and tumorigenicity in esophageal squamous cell carcinoma

Analysis of SOX9 Expression in Colorectal Cancer.

Sox9 Regulates Self-Renewal and Tumorigenicity by Promoting Symmetrical Cell Division of Cancer Stem Cells in Hepatocellular Carcinoma.

SOX9/FXYD3/Src Axis is Critical for ER+ Breast Cancer Stem Cell Function.

Expression analysis of SOX2 and SOX9 in patients with oral squamous cell carcinoma

CA9 transcriptional expression determines prognosis and tumour grade in tongue squamous cell carcinoma patients

Bmi1 Drives Stem-Like Properties and is Associated with Migration, Invasion, and Poor Prognosis in Tongue Squamous Cell Carcinoma

SOX9+ malignant cells define a poor prognosis subtype of Glioma with tumor-associated macrophage recruitment

SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types

The Role of SOX2 and SOX9 in Radioresistance and Tumor Recurrence

Expression of SOX9 in Colorectal Cancer and Its Significance

The multiple roles for Sox2 in stem cell maintenance and tumorigenesis

SOX5 Predicts Poor Prognosis in Lung Adenocarcinoma and Promotes Tumor Metastasis Through Epithelial-Mesenchymal Transition

SOX9-activated FARSA-AS1 predetermines cell growth, stemness, and metastasis in colorectal cancer through upregulating FARSA and SOX9

The Hippo Effector TAZ Promotes Cancer Stemness by Transcriptional Activation of SOX2 in Head Neck Squamous Cell Carcinoma

Upregulation of SOX9 promotes cell proliferation, migration and invasion in lung adenocarcinoma.

Sox9/CXCL5 axis facilitates tumour cell growth and invasion in hepatocellular carcinoma

Association of SOX9 Expression with Sensitivity to CDK7 Inhibition and Overall Survival in Triple-Negative Breast Cancer.

Proliferation of hepatocellular carcinoma cells is inhibited by RNA interference on SOX9

Targeting oncogenic SOX2 in human cancer cells: therapeutic application